Dr. Wu’s laboratory will perform in vivo study in mice to assess the therapeutic efficacy of CanCure’s therapeutic antibody in combination with standard care of hormone therapy for prostate cancer. Specifically, Dr. Wu’s lab will administrate CanCure’s therapeutic reagent and monitor the effect on tumor growth in mice.
|Effective start/end date||11/8/19 → 8/31/21|
- CanCure LLC (1001NU//1R44CA247503-02)
- National Cancer Institute (1001NU//1R44CA247503-02)